Abstract. Background. Aim. Patients and Methods. Patients. Study Design
|
|
- Philippa Gallagher
- 5 years ago
- Views:
Transcription
1 Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M. Choustermn, M. Vrstet, 5 M. Rotily, 5 T. Fontnges, 6. Mrcellin, 7. Ccoub 8 1 Hôpitl Générl, Sint Dizier, Frnce; Centre Hospitlier Erstein, Erstein, Frnce; 3 Institut Arnud Tznck, Sint Lurent du Vr, Frnce; Hôpitl de Créteil, Créteil, Frnce; 5 ClinSerch, Bgneux, Frnce; 6 Centre de l Appreil Digestif, Bourgoin Jllieu, Frnce; 7 Hôpitl Beujon, Clichy, Frnce; 8 Hôpitl itié-slpêtrière, ris, Frnce Abstrct Bckground nd ims: CHEOBS is French multicenter, prospective, observtionl study tht imed to nlyse the fctors ssocited with dherence to tretment with peginterferon lfb nd ribvirin in chronic heptitis C ptients. The present nlysis focuses on dherence to ntivirl dul therpy, virologicl response, nd qulity of life (QoL) ccording to whether the ptients were ctive drug users or under substitution tretment (), ex-drug users (), or non-drug users (). tients nd methods: Between 3 nd 6, 18 clinicins evluted 1 heptitis C ptients every 3 months during tretment nd 6 months fter the end of tretment. Among these ptients, 11 were excluded from the nlysis. The studied popultion included, 578 nd 138. Good dherence ws defined by >8% of the dose nd durtion of the ntivirl dul therpy prescribed. Sustined virologicl response (SVR) ws defined by negtive CR 1 weeks fter the end of tretment. QoL ws ssessed using the SF-36 questionnire. Results: The ptient profile in the group ws between tht in the nd groups for men ge, body mss index (BMI), liver fibrosis, level of eduction or debt difficult to mnge, high consumption of lcohol, psychitric disorders, or chronic diseses. The proportion of good dherents to dul therpy ws similr in ll three groups:, 9.%;, %;, 5.% (p=.7). The SVR rte ws lso similr: 9.3%, 5.9%, nd 57.8%, respectively (p=.1). The QoL in the group ws less ltered on the physicl nd mentl levels thn in the other groups. Conclusions: The rte of SVR ws similr in the three groups. Excess consumption of lcohol, precrious socioeconomic sitution, nd the psychitric disorders observed in drug users in this study hd no negtive impct on the tretment outcomes. On the contrry, young ge, recent contmintion, high prevlence of genotype 3 infection, lower BMI, less severe liver fibrosis, nd good dherence to tretment seem to hve blnced the negtive prmeters. Bckground The French Consensus Conference of Februry recommended treting ptients infected with heptitis C virus (HCV) with stble drug use 1 Key findings from the Hepcom Study, 1-month, multicenter, observtionl prospective study of tretment-nive chronic heptitis C ptients treted in the French helth cre system, were : Only one-third of ptients with ccess to helth cre initited ntivirl tretment Access to tretment ws more difficult mong these ptient popultions: Women HIV-coinfected ptients Drug users receiving substitution therpy Dt from Hepcom reveled tht helth cre ccess ws still limited for drug users, suggesting tht further study of this ptient popultion ws needed Aim This nlysis from the CHEOBS study compred the efficcy, tolerbility, complince, nd effect on qulity of life of pegylted interferon (EG-IFN) lfb (egintron ; Schering-lough) + ribvirin (RBV) in 3 groups of ptients with chronic heptitis C Non-drug users () Ex-drug users () Active drug users or users undergoing substitution tretment () tients nd Methods tients tients ged 18 nd older who hd chronic heptitis C nd initited tretment with EG-IFN lfb (1.5 µg/kg/wk) lone or in combintion with RBV (8-1 mg/d, depending on body weight) were eligible for enrollment tients were tretment nive or were nonresponders or relpsers to previous nti-hcv therpy Study Design The CHEOBS study ws prospective, multicenter, observtionl study conducted between 3 nd 6 tients were enrolled from 18 centers in Frnce tht specilize in the mngement of heptitis C Questionnires Both the investigtor nd the ptient completed questionnires t bseline, pproximtely every 3 months during tretment, nd 6 months fter tretment cesstion The investigtor questionnire collected the following informtion: tient sociodemogrphic dt Therpeutic eduction provided to the ptient History of HCV infection lnned heptitis C tretment History of psychoctive drug use Tretment modifictions Heptitis C therpy received before inclusion Virologic sttus of the ptient 6 months fter in the CHEOBS study tretment cesstion tient self-questionnires collected the following informtion: Qulity-of-life ssessment (SF-36 form) Complince with EG-IFN lfb + RBV tretment Results This nlysis includes 1 ptients who were clssified s,, nd (including ptients undergoing substitution therpy) (Figure 1) Of the, 7 ptients were receiving methdone therpy nd 137 were receiving buprenorphine substitution tretment Figure 1. tient flow digrm. HCV = heptitis C virus. Non-drug users n = 138 tients with chronic HCV infection N = 1 Anlyzed n = 1 Ex-drug users tient sociodemogrphics, comorbidities, nd risk fctors re shown in Tble 1 Heptitis C disese chrcteristics for enrolled ptients re shown in Tble Tble 1. Bseline Chrcteristics of tients Excluded: n = 11 - Monotherpy (n = 37) - Dte of cesstion of combintion therpy unknown (n = 79) - Virologic response unknown (n = 5) Active drug users or substituted ptients n = 138 Sociodemogrphics n/n (%) n/n (%) n/n (%) Men 51/135 (9) 8/578 (7) 198/3 (8) <.1 Age, y, men ± SD 51.7 ± ± ± 6. <.1 BMI, kg/m, men ± SD 5.3 ± ±. 3. ± 3.7 <.1 Employment sttus <.1 rofessionl ctivity 5/135 (56) 385/578 (67) 138/ (57) Unemployed 7/135 (7) 11/578 () 88/ (36) Other 39/135 (38) 79/578 (1) 18/ (7) Eduction level <.1 Low 57/13 (56) 337/569 (59) 18/ () High 53/13 () 3/569 (1) 6/ (5) Indebtedness <.1 Difficult to mnge 3/83 () /71 (9) 8/6 (1) None or esy to mnge 8/83 (96) 9/71 (91) 178/6 () Comorbidities sychitric history Depression 183/136 (18) 1/578 (3) 95/ (39) <.1 Suicide ttempt 31/13 (3) 8/577 (8) 5/1 (19) <.1 Hospitliztion for mentl illness 6/131 (5) 63/5 (11) 7/ (19) <.1 sychitric illnesses 168/13 (16) 138/576 () 97/ () <.1 Other chronic illnesses 366/1 (36) 95/571 (17) 3/39 (13) <.1 Risk fctors Alcohol consumption, > g/d 3/169 (1) /187 () 3/93 (37) <.1 Tobcco consumption 18/11 (1) /569 () 17/ (9) <.1 = ctive drug user or user undergoing substitution tretment; BMI = body mss index; = ex-drug user; = non-drug user. Tble. Heptitis C Disese Chrcteristics nd Etiology n = 138 Source of HCV infection n/n (%) n/n (%) n/n (%) Trnsfusion 7/119 (7) 19/578 (3) 3/ (1) <.1 Drug buse 1/119 (1) 56/578 (95) 3/ (96) <.1 Other 5/119 (53) 8/578 (5) 9/ () <.1 Durtion of HCV infection, y, men ± SD 3.5 ± ± ± 7. <.1 Serum HCV RNA.1 8, IU/mL /77 (57) /3 (56) 116/18 (6) >8, IU/mL 33/77 (3) 19/3 () 66/18 (36) HIV coinfection 1/13 (1) 38/578 (7) 15/ (6).1 HBV coinfection 6/15 (1) 1/5 () 8/1 (3).3 METAVIR ctivity grde or equivlent. A or A1 8/891 (6) 1/89 (9) 7/19 (39) A or A3 83/891 (5) 8/89 (51) 118/19 (6) METAVIR fibrosis stge or equivlent.5 F or F1 31/895 (3) 17/9 (35) 7/193 (38) F or F3 39/895 (9) 5/9 (51) 13/193 (53) F 155/895 (17) 68/9 (1) 16/193 (8) = ctive drug user or user undergoing substitution tretment; = ex-drug user; HBV = heptitis B virus; HCV = heptitis C virus; HIV = humn immunodeficiency virus; = non-drug user. Or equivlent. The distribution of genotypes ws significntly different cross the 3 ptient groups (.1; Figure ) The proportions of ptients with genotype 3 infection were higher mong nd thn mong Among, most ptients hd genotype 1 or infection Figure. Distribution of genotypes Genotype 1 Genotype Genotype 3 Genotypes, 5, 6 Tretment Dosing, Durtion, nd Adherence There ws significnt heterogeneity cross the ptient groups in terms of durtion of tretment nd dosing of EG-IFN lfb (.1; Tble 3) Men durtion of therpy ws longer in thn in or Men EG-IFN lfb doses were higher in thn in or 9.9 Tble 3. Investigtor-Reported Dose nd Durtion n = 138 Men durtion of tretment, wk 37. ± ± ± 16.6 <.1 Erly discontinution 315/138 (3) 169/578 (9) 79/ (3).653 Therpeutic eduction 6/138 (58) 35/578 (56) 16/ (66).1 Men cumultive dosge EG-IFN lfb, µg/kg/wk 1.3 ± ±.7 1. ±.1.1 Ribvirin, mg/d 89 ± ± ± Men dosge t lst tretment EG-IFN lfb, µg/kg/wk 1.3 ± ±.3 1. ±.3 <.1 Ribvirin, mg/d 879 ± 897 ± ± Vlues re men ± SD or n/n (%). = ctive drug user or user undergoing substitution tretment; = ex-drug user; = non-drug user. < weeks genotype 1 (G1), G, G5, nd G6 infection; < weeks for G nd G3 infection. Adherence (>8% of the recommended dose of EG-IFN lfb nd RBV for >8% of the recommended durtion [ccording to genotype]) to therpy ws similr in ll ptient groups (Figure 3) Figure 3. Adherence to EG-IFN lfb + ribvirin therpy. 1 5 =.598 =. =.7 = Virologic Response Virologic response rtes ssessed t lest 1 weeks fter completion of therpy were not significntly different mong ptient groups (Figure ) Figure. Virologic response rtes t lest 1 weeks fter end of tretment Qulity of Life = Sustined virologic response = Nonresponse 8.3 Chnges in qulity-of-life scores throughout tretment re shown in Figure 5 Figure 5. Qulity of life (SF-36 form): mentl (top) nd physicl (bottom) composite scores. Men Chnge From Bseline Men Chnge From Bseline =.13 =.9 =.16 = Relpse = Month 3 Month 6 Month 1 osttretment =.7 =.9 = = Month 3 Month 6 Month 1 osttretment The incidence of dverse events is shown in Figure 6 Mentl dverse events were more common mong t month 3 nd month 1 thn mong nd Figure 6. All dverse events (top) nd ll mentl dverse events (bottom) =.16 =.91 =.1 = Mentl =. =.89 =.7 = Summry In this study, there ws predominnce of genotype 3 infection mong nd Adherence to therpy nd virologic response rtes were similr in,, nd Mentl dverse events were more frequent mong ; however, combintion therpy hd less negtive impct on qulity of life in these ptients thn in or Conclusions In this nlysis, ctive drug use ws frequently ssocited with excessive lcohol intke, vulnerble socioeconomic sitution, nd psychitric illness However, ctive drug use did not hve negtive impct on Adherence to EG-IFN lfb + RBV combintion therpy Rte of premture discontinution Sustined virologic response rte It is possible tht predominnce of fvorble chrcteristics, such s young ge, recent HCV infection, high prevlence of genotype 3 infection, low body mss index, nd less dvnced stge of fibrosis counterblnced the potentilly negtive impct of the unfvorble prmeters ssocited with ctive drug use References 1. Consensus Conference: Tretment of Heptitis C; Februry 78, ; ris, Frnce. Accessed October 6, 8.. Agostini H et l. Gstroenterol Clin Biol. 7;31: Disclosures. Melin, J.-. Lng, D. Ouzn, M. Choustermn, M. Rotily, T. Fontnges,. Mrcellin, nd. Ccoub re consultnts for Schering-lough Frnce. M. Vrstet hs nothing to disclose. 56. resented t the th Annul Meeting of the Europen Assocition for the Study of the Liver, April 6, 9, Copenhgen, Denmrk
2 Impct of the resented Chronic Heptitis 1 Hôpitl Générl, S Abstrct Bckground nd ims: CHEOBS is French multicenter, prospective, observtionl study tht imed to nlyse the fctors ssocited with dherence to tretment with peginterferon lfb nd ribvirin in chronic heptitis C ptients. The present nlysis focuses on dherence to ntivirl dul therpy, virologicl response, nd qulity of life (QoL) ccording to whether the ptients were ctive drug users or under substitution tretment (), ex-drug users (), or non-drug users (). tients nd methods: Between 3 nd 6, 18 clinicins evluted 1 heptitis C ptients every 3 months during tretment nd 6 months fter the end of tretment. Among these ptients, 11 were excluded from the nlysis. The studied popultion included, 578 nd 138. Good dherence ws defined by >8% of the dose nd durtion of the ntivirl dul therpy prescribed. Sustined virologicl response (SVR) ws defined by negtive CR 1 weeks fter the end of tretment. QoL ws ssessed using the SF-36 questionnire. Results: The ptient profile in the group ws between tht in the nd groups for men ge, body mss index (BMI), liver fibrosis, level of eduction or debt difficult to mnge, high consumption of lcohol, psychitric disorders, or chronic diseses. The proportion of good dherents to dul therpy ws similr in ll three groups:, 9.%;, %;, 5.% (p=.7). The SVR rte ws lso similr: 9.3%, 5.9%, nd 57.8%, respectively (p=.1). The QoL in the group ws less ltered on the physicl nd mentl levels thn in the other groups. Conclusions: The rte of SVR ws similr in the three groups. Excess consumption of lcohol, precrious socioeconomic sitution, nd the psychitric disorders observed in drug users in this study hd no negtive impct on the tretment outcomes. On the contrry, young ge, recent contmintion, high prevlence of genotype 3 infection, lower BMI, less severe liver fibrosis, nd good dherence to tretment seem to hve blnced the negtive prmeters. Bckground The French Consensus Conference of Februry recommended treting ptients infected with heptitis C virus (HCV) with stble drug use 1 Key findings from the Hepcom Study, 1-month, multicenter, observtionl prospective study of tretment-nive chronic heptitis C ptients treted in the French helth cre system, were : Only one-third of ptients with ccess to helth cre initited ntivirl tretment Access to tretment ws more difficult mong these ptient popultions: Women HIV-coinfected ptients Drug users receiving substitution therpy Dt from Hepcom reveled tht helth cre ccess ws still limited for drug users, suggesting tht further study of this ptient popultion ws needed Aim This nlysis from the CHEOBS study compred the efficcy, tolerbility, complince, nd effect on qulity of life of pegylted interferon (EG-IFN) lfb (egintron ; Schering-lough) + ribvirin (RBV) in 3 groups of ptients with chronic heptitis C Non-drug users () Ex-drug users () Active drug users or users undergoing substitution tretment () tients nd Methods tients tients ged 18 nd older who hd chronic heptitis C nd initited tretment with EG-IFN lfb (1.5 µg/kg/wk) lone or in combintion with RBV (8-1 mg/d, depending on body weight) were eligible for enrollment tients were tretment nive or were nonresponders or relpsers to previous nti-hcv therpy Study Design The CHEOBS study ws prospective, multicenter, observtionl study conducted between 3 nd 6 tients were enrolled from 18 centers in Frnce tht specilize in the mngement of heptitis C
3 e Use of Drugs nd S C: Anlysis of Compl. Melin, 1 J.-. Lng, D. Ouzn Sint Dizier, Frnce; Centre Hospitlier Erstein, Erstein, F 6 Centre de l Appreil Digestif, Bourgoi Questionnires Both the investigtor nd the ptient completed questionnires t bseline, pproximtely every 3 months during tretment, nd 6 months fter tretment cesstion The investigtor questionnire collected the following informtion: tient sociodemogrphic dt Therpeutic eduction provided to the ptient History of HCV infection lnned heptitis C tretment History of psychoctive drug use Tretment modifictions Heptitis C therpy received before inclusion Virologic sttus of the ptient 6 months fter in the CHEOBS study tretment cesstion tient self-questionnires collected the following informtion: Qulity-of-life ssessment (SF-36 form) Complince with EG-IFN lfb + RBV tretment Results. This nlysis includes 1 ptients who were clssified s,, nd (including ptients undergoing substitution therpy) (Figure 1) Of the, 7 ptients were receiving methdone therpy nd 137 were receiving buprenorphine substitution tretment Figure 1. tient flow digrm. HCV = heptitis C virus. s e Non-drug users n = 138 tients with chronic HCV infection N = 1 Anlyzed n = 1 Ex-drug users Excluded: n = 11 - Monotherpy (n = 37) - Dte of cesstion of combintion therpy unknown (n = 79) - Virologic response unknown (n = 5) Active drug users or substituted ptients tient sociodemogrphics, comorbidities, nd risk fctors re shown in Tble 1 Heptitis C disese chrcteristics for enrolled ptients re shown in Tble ) Tble 1. Bseline Chrcteristics of tients n = 138 Sociodemogrphics n/n (%) n/n (%) n/n (%) Men 51/135 (9) 8/578 (7) 198/3 (8) <.1 Age, y, men ± SD 51.7 ± ± ± 6. <.1 BMI, kg/m, men ± SD 5.3 ± ±. 3. ± 3.7 <.1 Employment sttus <.1 rofessionl ctivity 5/135 (56) 385/578 (67) 138/ (57) Unemployed 7/135 (7) 11/578 () 88/ (36) Other 39/135 (38) 79/578 (1) 18/ (7) Eduction level <.1 Low 57/13 (56) 337/569 (59) 18/ () High 53/13 () 3/569 (1) 6/ (5) Indebtedness <.1 Difficult to mnge 3/83 () /71 (9) 8/6 (1) None or esy to mnge 8/83 (96) 9/71 (91) 178/6 () Comorbidities sychitric history Depression 183/136 (18) 1/578 (3) 95/ (39) <.1 Suicide ttempt 31/13 (3) 8/577 (8) 5/1 (19) <.1 Hospitliztion for mentl illness 6/131 (5) 63/5 (11) 7/ (19) <.1 sychitric illnesses 168/13 (16) 138/576 () 97/ () <.1 Other chronic illnesses 366/1 (36) 95/571 (17) 3/39 (13) <.1 Risk fctors Alcohol consumption, > g/d 3/169 (1) /187 () 3/93 (37) <.1 Tobcco consumption 18/11 (1) /569 () 17/ (9) <.1 = ctive drug user or user undergoing substitution tretment; BMI = body mss index; = ex-drug user; = non-drug user. ed t the th Annul Meeting of the Euro
4 ubstitution Tretmen lince, Virologicl Re, 3 M. Choustermn, M. Vrstet, 5 M. Rotily, 5 T. Fontnge Frnce; 3 Institut Arnud Tznck, Sint Lurent du Vr, Fr in Jllieu, Frnce; 7 Hôpitl Beujon, Clichy, Frnce; 8 Hôp Tble. Heptitis C Disese Chrcteristics nd Etiology n = 138 Source of HCV infection n/n (%) n/n (%) n/n (%) Trnsfusion 7/119 (7) 19/578 (3) 3/ (1) <.1 Drug buse 1/119 (1) 56/578 (95) 3/ (96) <.1 Other 5/119 (53) 8/578 (5) 9/ () <.1 Durtion of HCV infection, y, men ± SD 3.5 ± ± ± 7. <.1 Serum HCV RNA.1 8, IU/mL /77 (57) /3 (56) 116/18 (6) >8, IU/mL 33/77 (3) 19/3 () 66/18 (36) HIV coinfection 1/13 (1) 38/578 (7) 15/ (6).1 HBV coinfection 6/15 (1) 1/5 () 8/1 (3).3 METAVIR ctivity grde or equivlent. A or A1 8/891 (6) 1/89 (9) 7/19 (39) A or A3 83/891 (5) 8/89 (51) 118/19 (6) METAVIR fibrosis stge or equivlent.5 F or F1 31/895 (3) 17/9 (35) 7/193 (38) F or F3 39/895 (9) 5/9 (51) 13/193 (53) F 155/895 (17) 68/9 (1) 16/193 (8) = ctive drug user or user undergoing substitution tretment; = ex-drug user; HBV = heptitis B virus; HCV = heptitis C virus; HIV = humn immunodeficiency virus; = non-drug user. Or equivlent. The distribution of genotypes ws significntly different cross the 3 ptient groups (.1; Figure ) The proportions of ptients with genotype 3 infection were higher mong nd thn mong Among, most ptients hd genotype 1 or infection Figure. Distribution of genotypes Genotype 1 Genotype Genotype 3 Genotypes, 5, 6 Tretment Dosing, Durtion, nd Adherence There ws significnt heterogeneity cross the ptient groups in terms of durtion of tretment nd dosing of EG-IFN lfb (.1; Tble 3) Men durtion of therpy ws longer in thn in or Men EG-IFN lfb doses were higher in thn in or open Assocition for the Study of the L
5 ts on the Antivirl Tre sponse nd Qulity o s, 6. Mrcellin, 7. Ccoub 8 nce; Hôpitl de Créteil, Créteil, Frnce; 5 ClinSerch, B itl itié-slpêtrière, ris, Frnce Tble 3. Investigtor-Reported Dose nd Durtion n = 138 Men durtion of tretment, wk 37. ± ± ± 16.6 <.1 Erly discontinution 315/138 (3) 169/578 (9) 79/ (3).653 Therpeutic eduction 6/138 (58) 35/578 (56) 16/ (66).1 Men cumultive dosge EG-IFN lfb, µg/kg/wk 1.3 ± ±.7 1. ±.1.1 Ribvirin, mg/d 89 ± ± ± Men dosge t lst tretment EG-IFN lfb, µg/kg/wk 1.3 ± ±.3 1. ±.3 <.1 Ribvirin, mg/d 879 ± 897 ± ± Vlues re men ± SD or n/n (%). = ctive drug user or user undergoing substitution tretment; = ex-drug user; = non-drug user. < weeks genotype 1 (G1), G, G5, nd G6 infection; < weeks for G nd G3 infection. Adherence (>8% of the recommended dose of EG-IFN lfb nd RBV for >8% of the recommended durtion [ccording to genotype]) to therpy ws similr in ll ptient groups (Figure 3) Figure 3. Adherence to EG-IFN lfb + ribvirin therpy. 1 =.598 =. =.7 = Virologic Response Virologic response rtes ssessed t lest 1 weeks fter completion of therpy were not significntly different mong ptient groups (Figure ) Figure. Virologic response rtes t lest 1 weeks fter end of tretment = = = Sustined virologic response Nonresponse Relpse Qulity of Life Chnges in qulity-of-life scores throughout tretment re shown in Figure 5 Figure 5. Qulity of life (SF-36 form): mentl (top) nd physicl (bottom) composite scores. Men Chnge From Bseline Men Chnge From Bseline =.13 =.9 = = Month 3 Month 6 Month 1 osttretment =.7 =.9 = = Month 3 Month 6 Month 1 osttretment iver, April 6, 9, Copenhgen, De
6 etment of f Life (CHEOBS) gneux, Frnce; The incidence of dverse events is shown in Figure 6 Mentl dverse events were more common mong t month 3 nd month 1 thn mong nd Figure 6. All dverse events (top) nd ll mentl dverse events (bottom). 1 =.16 =.91 =.1 = Mentl =. =.89 =.7 = Summry In this study, there ws predominnce of genotype 3 infection mong nd Adherence to therpy nd virologic response rtes were similr in,, nd Mentl dverse events were more frequent mong ; however, combintion therpy hd less negtive impct on qulity of life in these ptients thn in or Conclusions In this nlysis, ctive drug use ws frequently ssocited with excessive lcohol intke, vulnerble socioeconomic sitution, nd psychitric illness However, ctive drug use did not hve negtive impct on Adherence to EG-IFN lfb + RBV combintion therpy Rte of premture discontinution Sustined virologic response rte It is possible tht predominnce of fvorble chrcteristics, such s young ge, recent HCV infection, high prevlence of genotype 3 infection, low body mss index, nd less dvnced stge of fibrosis counterblnced the potentilly negtive impct of the unfvorble prmeters ssocited with ctive drug use References 1. Consensus Conference: Tretment of Heptitis C; Februry 78, ; ris, Frnce. Accessed October 6, 8.. Agostini H et l. Gstroenterol Clin Biol. 7;31: Disclosures. Melin, J.-. Lng, D. Ouzn, M. Choustermn, M. Rotily, T. Fontnges,. Mrcellin, nd. Ccoub re consultnts for Schering-lough Frnce. M. Vrstet hs nothing to disclose. enmrk
Efficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationTHE CHB TREATMENT GUIDELINE NAVIGATOR REVIEW AN ONLINE INTERACTIVE GUIDE FOR CLINICIANS FEATURING EXPERT AUDIO COMMENTARY
The Americn Assocition for the Study of Liver Diseses () nd the Europen Assocition for the Study of Liver Disese () provide clinicl prctice guidelines for the mngement nd tretment of chronic heptitis B
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationY. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3
Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed
More informationAntiviral Therapy 2015; 20: (doi: /IMP2825)
Antivirl Therpy 2015; 20:209 216 (doi: 10.3851/IMP2825) Originl rticle Cost-effectiveness of boceprevir co-dministrtion versus pegylted interferon-2b nd ribvirin only for ptients with heptitis C genotype
More informationAntiviral Therapy 2017; 22:61 70 (doi: /IMP3085)
Antivirl Therpy 217; 22:61 7 (doi: 1.3851/IMP385) Originl rticle Comprison of the Abbott RelTime HCV nd Roche COBAS Ampliprep/COBAS TqMn HCV ssys for the monitoring of sofosbuvir-bsed therpy Eiichi Ogw
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationPresented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE
Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,
More informationMetabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction
Metbolic Syndrome nd Helth-relted Qulity of Life in Obese Individuls Seeking Weight Reduction Adm Gilden Tsi 1, Thoms A. Wdden 1, Dvid B. Srwer 1, Robert I. Berkowitz 1, Leslie G. Womble 1, Louise A. Hesson
More informationEfficacy of Sonidegib in Patients With Metastatic BCC (mbcc)
AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,
More informationCharacteristics of hip involvement in patients with ankylosing spondylitis in Korea
ORIGINAL ARTICLE Koren J Intern Med 2017;32:158-164 Chrcteristics of hip involvement in ptients with nkylosing spondylitis in Kore Hyemin Jeong, Yeong Hee Eun, In Young Kim, Hyungjin Kim, Jejoon Lee, Eun-Mi
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationA budget optimization analysis for the treatment and potential elimination of hepatitis C virus infection in the United States
A budget optimiztion nlysis for the tretment nd potentil elimintion of heptitis C virus infection in the United Sttes SAT-295 Olivier Ethgen,2, Yuri Snchez Gonzlez 3, Jordn J. Feld 4 SERFAN innovtion,
More informationFatigue and depressive symptoms associated with chronic viral hepatitis patients health-related quality of life (HRQOL)
Chronic virl heptitis nd HRQOL., 2010; 9 (4): 419-427 ORIGINAL ARTICLE October-December, Vol. 9 No.4, 2010: 419-427 419 Ftigue nd depressive symptoms ssocited with chronic virl heptitis ptients helth-relted
More informationHealth-Related Quality of Life and Symptoms of Depression in Extremely Obese Persons Seeking Bariatric Surgery
Oesity Surgery, 15, 3-39 Helth-Relted Qulity of Life nd Symptoms of Depression in Extremely Oese Persons Seeking Britric Surgery Anthony N. Frictore, PhD; Thoms A. Wdden, PhD; Dvid B. Srwer, PhD; Myles
More informationThe Association of Gender With Quality of Health in Peripheral Arterial Disease Following Peripheral Vascular Intervention
The Assocition of Gender With Qulity of Helth in Peripherl Arteril Disese Following Peripherl Vsculr Intervention Sudrshn Pudel, MD 1 ; Anwr Zitoun, MD 1 ; Sif Al-Njfi, MD 2 ; Ther Mus, MD 3 ; Susn Szpunr,
More informationSupplementary Online Content
Supplementry Online Content Rieckmnn N, Kronish IM, Shpiro PA, Whng W, Dvidson KW. Serotonin reuptke inhibitor use, depression, nd long-term outcomes fter n cute coronry : prospective cohort study. JAMA
More informationAssessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II
Assessment of Depression in Multiple Sclerosis Vlidity of Including Somtic Items on the Beck Depression Inventory II Peggy Crwford, PhD; Noh J. Webster, MA Signs nd symptoms of multiple sclerosis (MS)
More informationEstimating the impact of the 2009 influenza A(H1N1) pandemic on mortality in the elderly in Navarre, Spain
Rpid communictions Estimting the impct of the influenz pndemic on mortlity in the elderly in Nvrre, Spin J Cstill (jcstilc@nvrr.es) 1, J Etxeberri 1, E Ardnz 1, Y Floristán 1, R López Escudero 1, M Guevr
More informationThe Effects of Small Sized Rice Bowl on Carbohydrate Intake and Dietary Patterns in Women with Type 2 Diabetes
Originl Article doi: 10.4093/kdj.2010.34.3.166 pissn 1976-9180 eissn 2093-2650 The Effects of Smll Sized Rice Bowl on Crbohydrte Intke nd Dietry Ptterns in Women with Type 2 Dibetes Hee-Jung Ahn 1, *,
More informationOriginal Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:
Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute
More informationLarry Alphs 1*, Cynthia A Bossie 1, Jennifer K Sliwa 1, Yi-Wen Ma 2 and Norris Turner 1. Abstract
PRIMARY RESEARCH Open Access Onset of efficcy with cute long-cting injectble pliperidone plmitte tretment in mrkedly to severely ill ptients with schizophreni: post hoc nlysis of rndomized, double-blind
More informationPrognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic
Crcinogenesis, 2015, Vol. 36, No. 2, 243 248 doi:10.1093/crcin/bgu247 Advnce Access publiction December 18, 2014 Originl Mnuscript originl mnuscript Prognostic significnce of pretretment serum levels of
More informationImpact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors
Originl Article Impct of Positive Nodl Metstses in Ptients with Thymic Crcinom nd Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, nd Jennifer L. Sullivn, MD Introduction: Thymic crcinoms
More informationBody mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's health
Originl Article - Sexul Dysfunction/Infertility pissn 2005-6737 eissn 2005-6745 Body mss index, wist-to-hip rtio, nd metbolic syndrome s predictors of middle-ged men's helth Jung Hyun Prk *, In-Chng Cho
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationA series of recent studies and meta-analyses confirm
Originl Reserch Clinicl Medicine & Reserch Volume 11, Number 4: 210-218 2013 Mrshfield Clinic clinmedres.org Brest nd Prostte Cncer Survivors in Dibetic Cohort: Results from the Living With Dibetes Study
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationEffect on Glycemic, Blood Pressure, and Lipid Control according to Education Types
Originl Article http://dx.doi.org/10.4093/dmj.2011.35.6.580 pissn 2233-6079 eissn 2233-6087 D I A B E T E S & M E T A B O L I S M J O U R N A L Effect on Glycemic, Blood Pressure, nd Lipid Control ccording
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationPoster #822 Anlysis of Site Perf J. H. Jou, 1 M. S. Sulkowsk 1 Duke University Medicl Center nd Duke Clinicl Reserch Instit 5 Beth Isrel Liver Center,
Poster #822 Anlysis of Site Performnce in Acdemic nd Community-Bsed Centers in the IDEAL Study J. H. Jou, 1 M. S. Sulkowski, 2 K. R. Reddy, 3 S. L. Flmm, 4 N. H. Afdhl, 5 J. M. Levin, 6 V. K. Rustgi, 7
More informationChilblains (pernio, perniosis) are cold-induced, painful or itching
Nifedipine vs Plcebo for Tretment of Chronic Chilblins: A Rndomized Controlled Tril Ibo H. Souwer, MD 1 Jcobus H. J. Bor, BSc (Mth) 2 Pul Smits, MD, PhD 3 Antoine L. M. Lgro-Jnssen, MD, PhD 1 1 Deprtment
More informationManagement and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence
Clinicin Summry Mentl Helth Eting Disorders Mngement nd Outcomes of Binge-Eting Disorder in Adults: Current Stte of the Evidence Focus of This Summry This is summry of systemtic review evluting the evidence
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationInhaled Corticosteroid Is Associated With an Increased Risk of TB in Patients With COPD
CHEST Originl Reserch Inhled Corticosteroid Is Associted With n Incresed Risk of TB in Ptients With COPD Jung-Hyun Kim, MD ; Ji-Soo Prk, MD ; Kyung-Ho Kim, MD ; Hye-Cheol Jeong, MD ; Eun-Kyung Kim, MD
More informationBalapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients ( )
ORIGINAL ARTICLE Blpirvir plus peginterferon lf-2 (40KD)/ribvirin in heptitis C., 2012; 11 (1): 15-31 Jnury-Februry, Vol. 11 No.1, 2012: 15-31 15 Blpirvir plus peginterferon lf-2 (40KD)/ribvirin in rndomized
More informationLongitudinal Association of Maternal Attempt to Lose Weight During the Postpartum Period and Child Obesity at Age 3 Years
nture publishing group Longitudinl Assocition of Mternl Attempt to Lose Weight During the Postprtum Period nd Child Obesity t Age 3 Yers Kendrin R. Sonneville 1,2, Sheryl L. Rifs-Shimn 3, Emily Oken 3,
More informationSummary. Effect evaluation of the Rehabilitation of Drug-Addicted Offenders Act (SOV)
Summry Effect evlution of the Rehbilittion of Drug-Addicted Offenders Act (SOV) The Rehbilittion of Drug-Addicted Offenders Act (SOV) ws lunched on April first 2001. This lw permitted the compulsory plcement
More informationResults. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77)
Open-Lbel Extension of Rndomized, Double-Blind, Plcebo-Controlled, Phse 3 Study of the Sfety nd Anlgesic Efficcy of MNK-795 Oxycodone/Acetminophen Extended-Relese (OC/APAP ER) Tblets in n Acute Pin Model
More informationImpact of GP reminders on follow-up of abnormal cervical cytology:
Reserch Bettin Kjær Kristinsen, Berit Andersen, Flemming Bro, Hns Svnholm nd Peter Vedsted Impct of GP reminders on follow-up of bnorml cervicl cytology: before fter study in Dnish generl prctice Abstrct
More informationProposed Project Plan
Proposed Project Pln Comprison of triple conventionl synthetic disese-modifying ntirheumtic drugs nd biologic drugs or Jnus-ssocited kinse inhibitors for rheumtoid rthritis 28November 2018 BACKGROUND AND
More informationIMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC
IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,
More informationReference Slide Deck. Abstract 553 Abstract 554 Abstract 560
Clinicl Spotlight Immunotherpy Advnces for Colorectl Crcinom in 2018: Newly Relesed Dt From the Gstrointestinl Cncers Symposium in Sn Frncisco Reference Slide Deck Abstrct 553 Abstrct 554 Abstrct 560 Mismtch
More informationCheckMate-142 Study Design
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Thierry André, 1 Sr
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationAnemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project
Kidney Interntionl, Vol. 64 (2003), pp. 1120 1124 Anemi in peditric hemodilysis ptients: Results from the 2001 ESRD Clinicl Performnce Mesures Project DIANE L. FRANKENFIELD, ALICA M. NEU, BRADLEY A. WARADY,
More informationPrime Enrollees Consumer Watch NHC Patuxent River FY 2016 Defense Health Cost Assessment & Program Evaluation
Prime Enrollees Consumer Wtch NHC Ptuxent River 16 Defense Helth Cost Assessment & Progrm Evlution NHC Ptuxent River: Smple size-1,457 Response rte-1.2% Source: Helth Cre Survey of DoD Beneficiries Inside
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationPredictors of Sustained Six Months Quitting Success: Efforts of Smoking Cessation in Low Intensity Smoke-Free Workplaces
Originl Article Smoking Cesstion in Workplces Siti Munir Ysin et l 401 Predictors of Six Months Quitting Success: Efforts of Smoking Cesstion in Low Intensity Smoke-Free Workplces Siti Munir Ysin, 1 MBBS,
More informationClinicalTrials.gov Identifier: NCT
Efficcy of Drtumumb, Lenlidomide, nd Dexmethsone Versus Lenlidomide nd Dexmethsone in Relpsed or Refrctory Multiple Myelom Ptients With to 3 Prior Lines of Therpy: Updted Anlysis of POLLUX Sd Z. Usmni,
More informationFactors affecting screening for hepatocellular carcinoma
204 Al Hsni F, et l., 2014; 13 (2): 204-210 ORIGINAL ARTICLE Mrch-April, Vol. 13 No. 2, 2014: 204-210 Fctors ffecting screening for heptocellulr crcinom Frh Al Hsni,* Mrin Knoepfli, Armin Gemperli, Attil
More informationSeasonal influenza vaccination programme country profile: Ireland
Sesonl influenz vccintion progrmme country profile: Irelnd 2012 13 Seson Bckground informtion Influenz immunistion policy nd generl fcts bout Irelnd Volume indices of GDP per cpit in 2011 nd 2013 (EU-
More informationOriginal Investigation. management of type 2 diabetes mellitus.
Reserch Originl Investigtion Roux-en-Y Gstric Bypss Surgery or Lifestyle With Intensive Medicl Mngement in Ptients With Type 2 Dibetes Fesibility nd 1-Yer Results of Rndomized Clinicl Tril Florenci Hlperin,
More informationHealth Coaching: A Preliminary Report on the Effects in Traumatic Brain Injury/Polytrauma Patients
ORIGINAL RESEARCH Helth Coching: A Preliminry Report on the Effects in Trumtic Brin Injury/Polytrum Ptients Esmerld Mdrigl, MSW; Mx Gry, BA; Molly A. Timmermn, DO; Ttin Orozco, PhD; Dine Cowper Ripley,
More informationA cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis
Originl Article A cross-sectionl nd follow-up study of leukopeni in tuberculosis ptients: prevlence, risk fctors nd impct of nti-tuberculosis tretment Fei-Shen Lin 1 *, Mei-Ying Wu 2 *, Wen-Jun Tu 3, Hong-Qiu
More informationType 2 diabetes mellitus (T2DM) represents an emerging
At Glnce Prcticl Implictio p e102 Author Informtion p e107 Full text nd PDF Web exclusive Potentil Gender Differences of Exentide in Outptients With Type 2 Dibetes Mellitus Originl Reserch Antonio C. Bossi,
More informationRegistre des Tumeurs Digestives du Calvados, CJF INSERM 96-03, Faculté de Médecine, Avenue de Côte de nacre, Caen cedex, France;
British Journl of Cncer (1999) 81(2), 5 9 Article no. bjoc.1999.0692 Colorectl cncer fter negtive Hemoccult II test nd progrmme sensitivity fter first round of screening: the experience of the Deprtment
More informationAppendix J Environmental Justice Populations
Appendix J Environmentl Justice s [This pge intentionlly left blnk] Tble of Contents REFERENCES...J-2 Pge LIST OF TABLES Pge Tble J-1: Demogrphic Overview of Bruinsburg Site Project Are... J-3 Tble J-2:
More informationTarget: 10 mg/day within several days Schizophrenia in adolescents (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet
More informationEpilepsy & Behavior 20 (2011) Contents lists available at ScienceDirect. Epilepsy & Behavior. journal homepage:
Epilepsy & Behvior 20 (2011) 52 56 Contents lists vilble t ScienceDirect Epilepsy & Behvior journl homepge: www.elsevier.com/locte/yebeh Detecting helth disprities mong Cucsins nd Africn-Americns with
More informationOriginal Article INTRODUCTION. Korean Diabetes J 2010;34: doi: /kdj pissn eissn
Originl Article doi: 1.493/kdj.21.34.6.34 pissn 1976-918 eissn 293-265 The Smll Rice Bowl-Bsed Mel Pln ws Effective t Reducing Dietry Energy Intke, Body Weight, nd Blood Glucose Levels in Koren Women with
More informationInvasive Pneumococcal Disease Quarterly Report July September 2018
Invsive Pneumococcl Disese Qurterly Report July Septemer Introduction Since 17 Octoer 2008, invsive pneumococcl disese (IPD) hs een notifile to the locl Medicl Officer of Helth under the Helth Act 1956.
More informationMental health symptoms and patient-reported diabetes symptom burden: implications for medication regimen changes
Fmily Prctice, 2015, Vol. 32, No. 3, 317 322 doi:10.1093/fmpr/cmv014 Advnce Access publiction 5 April 2015 Helth Service Reserch Mentl helth symptoms nd ptient-reported dibetes symptom burden: implictions
More informationSymptom Management and Supportive Care
This mteril is protected y U.S. Copyright lw. Unuthorized reproduction is prohiited. For reprints contct: Reprints@AlphMedPress.com Symptom Mngement nd Supportive Cre Erly Intervention with Epoetin Alf
More informationMetformin and breast cancer stage at diagnosis: a population-based study
ORIGINAL ARTICLE METFORMIN AND BREAST CANCER STAGE AT DIAGNOSIS, Leg et l. Metformin nd brest cncer stge t dignosis: popultion-bsed study I.C. Leg md msc,* K. Fung msc,* P.C. Austin phd, nd L.L. Lipscombe
More informationReduced Trauma Symptoms and Perceived Stress in Male Prison Inmates through the Transcendental Meditation Program: A Randomized Controlled Trial
Reduced Trum Symptoms nd Perceived Stress in Mle Prison Inmtes through the Trnscendentl Medittion Progrm: A Rndomized Controlled Tril Snford Nidich, EdD; Tom O Connor, PhD; Thoms Rutledge, PhD; Jeff Duncn;
More informationRecall Bias in Childhood Atopic Diseases Among Adults in The Odense Adolescence Cohort Study
Syddnsk Universitet Recll Bis in Childhood Atopic Diseses Among Adults in The Odense Adolescence Cohort Study Mørtz, Chrlotte G; Andersen, Klus Ejner; Bindslev-Jensen, Crsten Published in: Act Dermto-Venereologic
More informationEFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE
Swine Dy 22 Contents EFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE B. J. Johnson, J. P. Kyser, J. D. Dunn, A. T. Wyln, S. S. Dritz 1, J.
More informationSponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)
These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005
More informationThe Acute Time Course of Concurrent Activation Potentiation
Mrquette University e-publictions@mrquette Exercise Science Fculty Reserch nd Publictions Exercise Science, Deprtment of 1-1-2010 The Acute Time Course of Concurrent Activtion Potentition Luke Grceu Mrquette
More informationOriginal Paper. Med Princ Pract 2017;26: DOI: /
Originl Pper Med Princ Prct 2017;26:146 151 Received: Mrch 28, 2016 Accepted: December 6, 2016 Published online: December 6, 2016 The Assocition of Vitmin D Sttus nd Vitmin D Replcement Therpy with Glycemic
More informationOriginal Article Clinical Care/Education INTRODUCTION DIABETES & METABOLISM JOURNAL
Originl Article Clinicl Cre/Eduction https://doi.org/10.4093/dmj.2018.42.1.28 pissn 2233-6079 eissn 2233-6087 DIABETES & METABOLISM JOURNAL Improvement of Glycosylted Hemoglobin in Ptients with Type 2
More informationkey words: chronic obstructive pulmonary disease, beta agonists, Medicare, health care costs, health care utilization
reserch report Helth Cre Use nd Costs Among Medicre Ptients With Chronic Obstructive Pulmonry Disese Treted With Short-Acting Bet Agonists or Long-Acting Bet Agonists Flvi Ejzykowicz, PhD; 1 Vmsi K Bollu,
More informationCardiovascular disease in persons with depressive & anxiety disorders
Crdiovsculr disese in persons with depressive & nxiety disorders 124 chpter 7 crdiovsculr disese in persons with depressive nd nxiety disorders 125 ABSTRACT Bckground Associtions between depression, nd
More informationOriginal Article. Breast Care 2016;11: DOI: /
Originl Article Brest Cre 2016;11:323 327 DOI: 10.1159/000452079 Published online: October 24, 2016 Neodjuvnt Chemotherpy with Docetxel, Crbopltin nd Weekly Trstuzumb Is Active in HER2-Positive Erly Brest
More informationDiabetes affects 29 million Americans, imposing a substantial
CLINICAL Comprtive Effectiveness nd Costs of Insulin Pump Therpy for Dibetes Ronld T. Ackermnn, MD, MPH; Amish Wlli, MD, MS; Rymond Kng, MA; Andrew Cooper, MPH; Theodore A. Prospect, FSA, MAAA; Lewis G.
More informationDoes increasing physical activity reduce the excess risk of work disability among overweight individuals? 1
1 Does incresing physicl ctivity reduce the excess risk of work disbility mong overweight individuls? 1 by Jenni Ervsti, PhD, 2 Jkko Airksinen, PhD, Jn Pentti, MSc, Jussi Vhter, MD, PhD, Skri Suominen,
More informationURINARY incontinence is an important and common
Urinry incontinence in older people in the community: neglected problem? Helen Stoddrt, Jenny Donovn, Elise Whitley, Deborh Shrp nd In Hrvey SUMMARY Bckground: The prevlence nd impct of urinry incontinence
More informationSymptoms of Sleep Disordered Breathing and Risk of Cancer: A Prospective Cohort Study
SYMPTOMS OF SDB AND RISK OF CANCER: A PROSPECTIVE COHORT STUDY http://dx.doi.org/10.5665/sleep.3030 Symptoms of Sleep Disordered Brething nd Risk of Cncer: A Prospective Cohort Study Anne Sofie Christensen,
More informationAge related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer
MOLECULAR AND CLINICAL ONCOLOGY 9: 329-334, 2018 Age relted differences in prognosis nd prognostic fctors mong ptients with epithelil ovrin cncer KENJI YOSHIKAWA, TAKESHI FUKUDA, RYO UEMURA, HIROAKI MATSUBARA,
More informationEffect of vitamin D on the recurrence rate of rheumatoid arthritis
1812 Effect of vitmin D on the recurrence rte of rheumtoid rthritis JUNXIA YANG 1, LIN LIU 1, QINGLIN ZHANG 2, MEIRONG LI 1 nd JINGYA WANG 1 1 Deprtment of Rheumtology, 2 Centrl Lbortory, Xuzhou Centrl
More informationDietary Sodium Intake in People with Diabetes in Korea: The Korean National Health and Nutrition Examination Survey for 2008 to 2010
Originl Article Epidemiology Dietes Met J 2016;40:290-296 http://dx.doi.org/10.4093/dmj.2016.40.4.290 pissn 2233-6079 eissn 2233-6087 DIABETES & METABOLISM JOURNAL Dietry Sodium Intke in People with Dietes
More informationInhaled Corticosteroids and the Risk of Pneumonia in People With Asthma
CHEST Originl Reserch Inhled Corticosteroids nd the Risk of Pneumoni in People With Asthm A Cse-Control Study Trici McKeever, PhD ; Timothy W. Hrrison, MD ; Richrd Hubbrd, MD ; nd Dominick Shw, MD ASTHMA
More informationOpioid Use and Survival at the End of Life: A Survey of a Hospice Population
532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,
More informationInfluence of the Duration of Diabetes on the Outcome of a Diabetes Self-Management Education Program
Originl Article Clinicl Cre/Eduction http://dx.doi.org/10.4093/dmj.2012.36.3.222 pissn 2233-6079 eissn 2233-6087 D I A B E T E S & M E T A B O L I S M J O U R N A L Influence of the Durtion of Dibetes
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationAntiviral Therapy 2014; 19: (doi: /IMP2721)
Antivirl Therpy 2014; 19:191 200 (doi: 10.3851/IMP2721) Originl rticle Chnge in vitmin D levels nd risk of severe vitmin D deficiency over 48 weeks mong HIV 1 infected, tretment-nive dults receiving rilpivirine
More informationThe Hepatitis C treatment landscape is changing in Pakistan
The Heptitis C tretment lndscpe is chnging in Pkistn 01 A new dwn hs emerged in ccess to HCV Cure Ferozsons is herlding the chnge in the Heptitis C lndscpe of Pkistn In prtnership with Giled Sciences,
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationHuman Immunodeficiency Virus / Acquired Immunodeficiency Syndrome Knowledge and Risk Factors in Ethiopian Military Personnel
MILITARY MEDICINE, 169, 3:221, 2004 Humn Immunodeficiency Virus / Acquired Immunodeficiency Syndrome Knowledge nd Risk Fctors in Ethiopin Militry Personnel Gurntor: Ludmil N. Bkhirev, MD MPH Contributors:
More informationEpidemiological survey and analysis of asthma in children aged 0-14 years old in urban and rural areas of Chengdu region
Originl Article Epidemiologicl survey nd nlysis of sthm in children ged 0-14 yers old in urbn nd rurl res of Chengdu region Min Li 1, Qiong Zhng 2, Wei-Jun Shi 2, Ln Li 1, Yn Li 2, Ying Png 1, Bin Yo 1,
More informationThis supplement to The American Journal of Managed Care is based
Decision Mker Forum in Mnged Cre expert consultnts John M. Kne, MD (Co-Chir) Professor, Psychitry, Neurology, nd Neuroscience Albert Einstein College of Medicine Chirmn, Deprtment of Psychitry The Zucker
More informationNonpharmacologic Interventions for Treatment-Resistant Depression in Adults Executive Summary
Comprtive Effectiveness Review Numer 33 Effective Helth Cre Progrm Nonphrmcologic Interventions for Tretment-Resistnt Depression in Adults Executive Summry Bckground Mjor depressive disorder (MDD) is common
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationResearch Article Use of Self-Care and Practitioner-Based Forms of Complementary and Alternative Medicine before and after a Diagnosis of Breast Cancer
Hindwi Publishing Corportion Evidence-Bsed Complementry nd Alterntive Medicine Volume 2013, Article ID 301549, 16 pges http://dx.doi.org/10.1155/2013/301549 Reserch Article Use of Self-Cre nd Prctitioner-Bsed
More information